Journal Article

Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4

Xu, Shuyi, Chen, Junsheng, Xie, Yueqing, Wu, Mingyuan, Hao, Shuai, Zhu, Shunying, Zhao, Meiqi, Zhu, Jianwei, Li, Liangzhu, Li, Yaxian, Jiang, Hua

2022

Overview

Background: Antibodies and derivative drugs targeting immune checkpoints have been approved for the treatment of several malignancies, but there are fewer responses in patients with pancreatic cancer. Here, we designed a nanobody molecule with bi-targeting on PD-L1 and CXCR4, as both targets are overexpressed in many cancer cells and play important roles in tumorigenesis. We characterized the biochemical and anti-tumour activities of the bispecific nanobodies in vitro and in vivo. Methods: A nanobody molecule was designed and constructed. The nanobody sequences targeting PD-L1 and CXCR4 were linked by the (G 4 S) 3 flexible peptide to construct the anti-PD-L1/CXCR4 bispecific nanobody. The bispecific nanobody was expressed in E. coli cells and purified by affinity chromatography. The purified nanobody was biochemically characterized by mass spectrometry, Western blotting and flow cytometry to confirm the molecule and its association with both PD-L1 and CXCR4. The biological function of the nanobody and its anti-tumour effects were examined by an in vitro tumour cell-killing assay and in vivo tumour inhibition in mouse xenograft models. Results: A novel anti-PD-L1/CXCR4 bispecific nanobody was designed, constructed and characterized. The molecule specifically bound to two targets on the surface of human cancer cells and inhibited CXCL12-induced Jurkat cell migration. The bispecific nanobody increased the level of IFN-γ secreted by T-cell activation. The cytotoxicity of human peripheral blood mononuclear cells (hPBMCs) against pancreatic cancer cells was enhanced by the molecule in combination with IL-2. In a human pancreatic cancer xenograft model, the anti-PD-L1/CXCR4 nanobody markedly inhibited tumour growth and was superior to the combo-treatment by anti-PD-L1 nanobody and anti-CXCR4 nanobody or treatment with atezolizumab as a positive control. Immunofluorescence and immunohistochemical staining of xenograft tumours showed that the anti-tumour effects were associated with the inhibition of angiogenesis and the infiltration of immune cells. Conclusion: These results clearly revealed that the anti-PD-L1/CXCR4 bispecific nanobody exerted anti-tumour efficacy in vitro and inhibited tumour growth in vivo. This agent can be further developed as a therapeutic reagent to treat human pancreatic cancer by simultaneously blocking two critical targets.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Affinity chromatography / Angiogenesis / Animal models / Animals / Antibodies, Bispecific - pharmacology / Antibodies, Bispecific - therapeutic use / Antibody / Apoptosis / B7-H1 Antigen - metabolism / Biomedical and Life Sciences / Biomedicine / Bispecific nanobody / Cancer Research / Cancer therapies / Cell activation / Cell migration / Cell surface antigens / Chemokines / Complications and side effects / CXCL12 protein / CXCR4 / CXCR4 protein / Cytotoxicity / Development and progression / Diagnosis / Drug delivery / Escherichia coli - metabolism / Flow cytometry / Health aspects / Health Promotion and Disease Prevention / Humans / Immune checkpoint / Immunofluorescence / Immunosuppressive agents / Immunotherapy / Interleukin 2 / Leukocytes (mononuclear) / Leukocytes, Mononuclear - metabolism / Ligands / Lymphocytes / Lymphocytes T / Malignancy / Mass spectroscopy / Medicine/Public Health / Metastases / Metastasis / Mice / Monoclonal antibodies / Nanobodies / Nanomedicine / Oncology / Pancreatic cancer / Pancreatic Neoplasms / Pancreatic Neoplasms - drug therapy / PD-L1 / PD-L1 protein / Prevention / Programmed Cell Death 1 Receptor / Proteins / Receptors, CXCR4 / Risk factors / Single-Domain Antibodies - pharmacology / Single-Domain Antibodies - therapeutic use / Surgical Oncology / Tumors / Western blotting / Xenografts / γ-Interferon